

GENOME THERAPEUTICS CORP

Form 8-K

March 08, 2004

---

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

Pursuant to

Section 13 or 15(d) of

**THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of Earliest Event Reported): March 5, 2004

---

**GENOME THERAPEUTICS CORP.**

(Exact name of registrant as specified in its charter)

---

Massachusetts  
(State or other jurisdiction

of incorporation)

0-10824  
(Commission

File Number)

04-2297484  
(I.R.S. Employer

Identification Number)

100 Beaver Street

Waltham, Massachusetts 02453

Edgar Filing: GENOME THERAPEUTICS CORP - Form 8-K

(Address of principal executive offices, including zip code)

(781) 398-2300

(Registrant's telephone number, including area code)

---

**ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.**

On March 5, 2004, Genome Therapeutics Corp. issued a press release announcing its financial results for its fourth fiscal quarter and year ended December 31, 2003. A copy of that press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.

The information in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act ) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**GENOME THERAPEUTICS CORP.**

By:                                 /s/ STEPHEN COHEN                                

**Name: Stephen Cohen**  
**Title: Senior Vice President and Chief Financial Officer**

Date: March 8, 2004

**EXHIBIT INDEX**

**Exhibit Number**

**Description**

99.1

Press Release issued by Genome Therapeutics Corp. on March 5, 2004.